Anti-aging vaccine
A nucleic acid-based vaccine targeting senescent cells with a recombinant protein and adjuvants addresses the limitations of current therapies by enhancing specificity and safety, prolonging lifespan and improving tissue function while reducing aging symptoms.
Patent Information
- Application Number
- PCT/RU2026/050095
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-14
- Filing Date
- 2026-04-21
- Publication Date
- 2026-11-19
AI Technical Summary
Current senolytic therapies, such as small-molecule drugs and cytotoxic antibodies, lack specificity and have significant side effects, while gene-based therapies are expensive and difficult to implement, necessitating the development of safer and more precise senolytic vaccines that target senescent cells without harming healthy tissue.
A nucleic acid-based vaccine encoding a recombinant protein with specifically selected epitopes of target proteins associated with aging, combined with immunogenic adjuvants, to stimulate the immune system to selectively eliminate senescent cells, using a combination of CTL and HTL epitopes and a reverse ER transport signal for enhanced immunogenicity and specificity.
The vaccine effectively prolongs lifespan by reducing senescent cell accumulation, maintains tissue function, and mitigates aging symptoms, offering broad-spectrum activity against multiple aging-related diseases with minimal side effects and cost-effectiveness.
Smart Images

Figure 00000037_0000 
Figure 00000037_0001
Abstract
Description
Anti-aging vaccine
[0001] The present invention relates generally to the field of healthcare, and in particular to a nucleic acid-based vaccine intended primarily to counteract aging, improve quality of life in old age, and maintain a healthier state of the body's organs and tissues, which is achieved by inducing an immune response against senescent cells and their elimination.
[0002] In particular, the invention relates to a nucleic acid molecule encoding an immunogenic protein, wherein the protein contains specifically selected epitopes of five target proteins associated with aging, as well as additional internal adjuvants. Furthermore, the invention encompasses objects based on the use of said nucleic acid molecule or related to its production.
[0003] Cell aging (senescence) is one of the key biological processes associated with age-related diseases and the overall decline of bodily functions. Senescent cells accumulate in tissues with age and contribute to the development of chronic inflammation, fibrosis, atherosclerosis, osteoarthritis, neurodegenerative disorders, cancer, and other conditions. Inflammatory responses are one of the primary external effects of senescent cells, suggesting a link between aging and altered intracellular communication. A key feature of senescent cells is the senescence-associated secretory phenotype (SASP), which involves the secretion of numerous bioactive factors, such as cytokines, chemokines, growth factors, and proteases.These factors have a significant effect on the cellular microenvironment and cause both positive functions (e.g. tissue repair) and negative ones, leading to chronic inflammation, induction of senescence in neighboring cells, and ultimately to tissue dysfunction, fibrosis, cancer progression, etc.
[0004] Combating senescent cells—senotherapy—has become a promising approach to combating age-related pathologies. There are two approaches to senotherapy: destroying senescent cells or minimizing their adverse effects on the body. Drugs that utilize these approaches are called senolytics and senomorphics, respectively.
[0005] Senolytics are drugs that selectively destroy senescent cells by inducing apoptosis. They can act through a wide range of aging mechanisms, including inhibition of intracellular pathways essential for senescent cells, depletion of metabolites critical for these cells, disruption of proteostasis and electrolyte balance, exacerbation of mitochondrial dysfunction, promotion of ROS (reactive oxygen species) accumulation, suppression of Na+ / K+-ATPase, which leads to destabilization of membrane potential and a decrease in intracellular pH, and many others. Encouraging results have been obtained in senolytic research. For example, one of the first senolytics with proven efficacy is a combination of the previously known dasatinib and quercetin. In addition, various other senolytic candidates have been identified.
[0006] However, the use of small-molecule senolytics and senomorphics has limitations, including lack of specificity and potential side effects. Methods for eliminating senescent cells using cytotoxic antibodies or CAR-T therapy have demonstrated relatively high specificity and efficacy in mouse experiments. However, these methods are difficult to implement and expensive, significantly limiting their widespread use.
[0007] These limitations have led to the need to develop more precise and safer methods, such as senolytic vaccines, which could selectively target senescent cells, stimulating the immune system to destroy them.
[0008] In recent years, significant advances have been made in the development of senolytic vaccines. One promising approach is targeting antigens that are specific markers of senescent cells, such as the proteins p16INK4a, p21, and other molecules associated with cellular senescence. These vaccines promote the activation of cytotoxic T lymphocytes and macrophages, leading to the selective elimination of senescent cells without damaging healthy tissue.
[0009] Nucleic acid-based vaccines (gene vaccines) are genetically engineered constructs that, when introduced into a cell, promote the production of immunogenic proteins (antigens), resulting in an immune response. Genetic immunization offers several advantages over conventional vaccines. For example, these vaccines are known to promote not only the production of antibodies (humoral immunity) but also a specific cytotoxic response (cellular immunity), something previously only achievable with live vaccines.
[0010] No gene vaccines encoding all or some of the antigens used in the vaccine of the invention have been previously described, but some research is underway on the target proteins upon which the present invention is based.
[0011] US2024287134 discloses a fusion protein incorporating several epitopes of Connexin 43 and its pseudogene product. The protein is intended for the prevention or treatment of osteoarthritis or aging-associated diseases caused by the persistence and accumulation of senescent cells (SSCs). US2020255489 discloses senolytic peptides that inhibit the action of FoxO4 on p53, which induces apoptosis of senescent cells. The authors claim that these peptides cause minimal side effects due to interactions with p53DBD, other FoxOs, and DNA. EP4491190 proposes modifying the Tvs1 protein from snake venom, previously known as an anticancer agent, to enhance its senolytic effect.
[0012] In the review by Vasilieva MI, Shatalova RO, Matveeva KS, Shindyapin VV, Minskaia E., Ivanov RA, Shevyrev DV Senolytic Vaccines from the Central and Peripheral Tolerance Perspective. Vaccines (Basel). 2024 Dec 10;12(12):1389, the current state of anti-aging vaccine development is characterized, some aging-associated protein targets and candidate vaccines under investigation for combating aging-related diseases are listed.
[0013] A vaccine based on the extracellular domain sequence of GPNMB (glycoprotein protein B of non-metastatic melanoma) is known. In an immunization experiment in mice pre-fed a high-fat diet, reduced GPNMB expression, a decrease in the number of senescent cells, and improved metabolic parameters were observed (Suda, M., Shimizu, I., Katsuumi, G. et al. Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. Nat Aging 1, 1117–1126 (2021)).
[0014] A vaccine is also known, which is a conjugate of the CD153 epitope and the KLH carrier protein, which showed a decrease in the number of senescent cells in a similar mouse model (Yoshida S, Nakagami H, Hayashi H, Ikeda Y, Sun J, Tenma A, Tomioka H, Kawano T, Shimamura M, Morishita R, Rakugi H. The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice. Nat Commun. 2020 May 18;11(1):2482).
[0015] Both the above mentioned anti-GPNMB and anti-CD153 vaccines can be considered as a prototype of the present invention.
[0016] However, further vaccine development is complicated by the antigenic heterogeneity of senescent cells and the lack of a single marker. As a result, there is a need for effective polyvalent vaccines specifically designed for senotherapy. Furthermore, there is a need for such vaccines in the form of gene-based vaccines. Such vaccines have not been described in the literature.
[0017] Another challenge facing developers is that, on the one hand, targeting certain senescent cell markers can lead to damage to healthy cells, while on the other, the immunogenicity of the body's own cells, which also include senescent cells, is naturally low. Therefore, peptide vaccines are needed that offer improved immunogenicity, broader activity against senescent cells, and, ideally, fewer side effects.
[0018] Finally, there is a general need for a wider range of senotherapeutic vaccines.
[0019] The present invention aims to solve the above-mentioned problems. The vaccine according to the invention differs from prior art vaccines at least in that it is based on a nucleic acid molecule and in its antigen design, which combines specifically selected epitopes of the corresponding target proteins and internal adjuvants.
[0020] To address the above-mentioned issues, the inventors developed a combined antigen with tissue-specific targets for the selective elimination of senescent cells and, secondly, presented it as a gene vaccine. The antigen includes CTL and HTL epitopes (epitopes for cytotoxic T lymphocytes and T helper cells, respectively) of antigenic targets, selected based on immunogenicity, with cross-reactivity between mouse and human sequences to enable vaccine testing in a mouse model.
[0021] More specifically, the subject of the invention is a recombinant nucleic acid molecule encoding an immunogenic protein, wherein the protein comprises, separated from each other by linkers, a fragment of HbhA, PADRE (pan-HLA DR-binding epitope), a group of HTL epitopes CD87, GPNMB, CD9, CD153 and KLRG1, a group of CTL epitopes CD87, GPNMB, CD9, CD153 and KLRG1, an epitope WT33 and a signal for reverse transport into the endoplasmic reticulum, wherein:
[0022] - the HbhA fragment is SEQ ID NO:2;
[0023] - PADRE is SEQ ID NO:3;
[0024] - the group of HTL epitopes CD87, GPNMB, CD9, CD153 and KLRG1 is a sequence consisting of SEQ ID NO: 4-12, separated from each other by rigid linkers;
[0025] - the group of CTL epitopes CD87, GPNMB, CD9, CD153 and KLRG1 is a sequence consisting of SEQ ID NO: 13-22, separated from each other by flexible linkers;
[0026] - epitope WT33 is SEQ ID NO:23;
[0027] - the reverse endoplasmic reticulum transport signal is SEQ ID NO:24;
[0028] The HbhA fragment is located at the N-terminus and is separated from PADRE by a rigid linker; PADRE is separated from the group of HTL or CTL epitopes by a rigid linker; the signal for reverse transport into the endoplasmic reticulum is located at the C-terminus and is separated by a flexible linker.
[0029] Preferably, the rigid linkers in each case are independently selected from (EAAAK) n , where n = 1-5; [A(EAAAK) n A] k , where k = 1 or 2, n = 1-5; A(EAAAK)4ALEA(EAAAK)4A; P k (XP) n , where k = 0 or 1, n = 2-34, X is any amino acid, preferably Ala, Lys or Glu, most preferably the rigid linkers are selected from EAAAK, AEAAAKEAAAKA or GPGPG; and the flexible linkers are selected from (GGGS) n or (GGGGS) n , where n = 1-9, (GGGGS) n AS, where n = 1-9, AGGGS(GGGGS) n , where n = 1-8, AGGGS(GGGGS) n AS, where n = 1-8, G n , where n = 5-20 (preferably 6 or 8), KESGSVSSEQLAQFRSLD, EGKSSGSGSESKST, GSAGSAAGSGEF, GGSSG, (GS) n , where n = 3-8, GGGGSLVPRGSGGGGS, GGSGGHMGSGG, GG(SGG) n , where n = 1-3, GGSGGGGG, (GGGSE)3GGG, AAGAATAA, GSGGGTGGGSG, (GS)4GGSG, GSGGGTGGGSG, GS(GGS)4, GSGGSGSGGSGGSG, most preferably the flexible linkers are selected from GGGS.
[0030] The invention as a whole does not impose any specific limitations on the type of said nucleic acid molecule, which may preferably be a plasmid vector, in particular a cloning plasmid or an expression plasmid; a viral vector, preferably an adenoviral vector, a lentiviral vector, a retroviral vector, an adeno-associated viral vector; or RNA, in particular mRNA, self-amplifying RNA or transamplifying RNA.
[0031] In one preferred embodiment, the nucleic acid molecule is a plasmid with the sequence SEQ ID NO:29.
[0032] Another object of the invention is a pharmaceutical composition comprising said nucleic acid molecule in an effective amount and one or more excipients. A method of senotherapy is provided, comprising administering an effective amount of said pharmaceutical composition to a subject in need.
[0033] In additional embodiments, a host cell is provided for producing said nucleic acid molecule, wherein said cell contains said nucleic acid, and a method for obtaining said nucleic acid molecule, comprising culturing said host cell under conditions that promote an increase in cell biomass, isolating the nucleic acid molecule from the biomass and purifying it.
[0034] Finally, the use of the said nucleic acid molecule as a medicinal product for senotherapy is envisaged.
[0035] The present invention provides, first of all, a statistically significant prolongation of the life of an organism, which is due to the elimination of senescent cells by the body's own immune system or the reduction or prevention of their accumulation in tissues or organs.
[0036] Targeting senescent cells may also result in the maintenance or normalization of tissue or organ function or health, or the prevention or delay of their dysfunction, or the mitigation of the symptoms or consequences of aging, particularly the SASP phenotype or the timing of the onset of the senescent phenotype, and improved quality of life.
[0037] In addition, the proposed vaccine has the following effects and advantages:
[0038] - senotherapy using the proposed peptide provides safe mitigation of the effects of aging and prolongation of healthy lifespan;
[0039] - since the antigen in the vaccine is based on target proteins that are associated in one way or another with certain diseases and conditions, such as cancer (e.g., melanoma, glioblastoma, and a number of others), infectious diseases, the vaccine will be useful in preventing or treating such diseases, as well as when it is necessary to modulate the immune response in relation to one or more targets;
[0040] - epitopes are selected taking into account the human HLA (major histocompatibility complex) supertypes A2, A3, B7, covering more than 80% of the population, which ensures the universality of the vaccine and the prospects for its global export;
[0041] - due to the presence of several epitopes from several of the most promising target proteins, the vaccine has a broad spectrum of activity with a single molecule; simultaneous vaccination against several targets facilitates compliance (adherence to the treatment regimen by patients);
[0042] - a nucleic acid-based vaccine can be easily produced and purified using conventional means and methods known in the art, especially when sold as a DNA vaccine, which will reduce the cost of its production and, therefore, make it available to a wide range of consumers. Detailed description of the invention Terminology
[0043] All terms used have the meanings accepted in the given field, unless a more specific or different interpretation is defined in this document or does not follow from the context.
[0044] The terms "chimeric", "hybrid", "recombinant" are used interchangeably with respect to the molecules of the invention and generally refer to a nucleic acid or protein that is created by joining parts (nucleotide or amino acid sequences) taken from different sources.
[0045] The terms "polynucleotide," "nucleic acid," and "nucleic acid molecule" refer to natural or synthetic polymers formed from nucleotide residues. Polynucleotides include DNA, RNA, and modified forms, and functionally can be vectors or any other type of molecule, such as mRNA. Vectors are defined as any molecule used to transfer genetic material into a cell. Vectors include, but are not limited to, plasmids, phasmids, and vectors based on RNA or DNA viruses, such as adenoviruses, herpesviruses, retroviruses, adeno-associated virus, SV40, and others. Vectors can be cloning or expression vectors.
[0046] The terms "transformation", "transfection", "transduction" are used interchangeably to describe the process of introducing nucleic acid into a host cell or organism.
[0047] The term "isolated" or "isolated," depending on the context, means a single protein or nucleic acid molecule that is not part of (a portion of) a larger molecule, and / or a molecule separated from the mixture or environment in which it was obtained or originally found. Accordingly, the molecules of the invention may be isolated, but are not limited to this.
[0048] The terms "antigens" and "antigenic determinants" refer to a molecule or molecular structure recognized by an antigen receptor, such as antibodies or their fragments, T-cell receptors, and other binding structures. Antigens contain one or more epitopes—characteristic structural features of the antigen (antigenic determinants). An antigen can be an immunogen, i.e., capable of eliciting humoral and / or cellular immunity. Depending on the context, for simplicity, an antigen can also refer to the entire fusion immunogenic protein according to the invention, as well as the coding sequence within the nucleic acid molecule.
[0049] When using terms in the singular, it is implied, where the context permits, that the plural is also possible, and vice versa.
[0050] The terms "including," "containing," "having," and the like mean that, in addition to the specified elements, other unspecified (nonessential) elements known to those skilled in the art may be present. In each case, these terms also encompass the meaning of "consisting of," meaning that, in one embodiment, they imply that the described object is characterized by the presence of only the specified elements.
[0051] The numerical values mentioned imply both the exact value indicated and an approximate value corresponding to it (the terms “about”, “approximately”, “approximately” are also used for this), which is determined by a deviation upward and / or downward by 10, 5, 2 or 1%, or, in the case of parameters that can be measured with a certain accuracy, within the limits of measurement error characteristic of traditional measuring instruments.
[0052] The default intervals provided imply that both the boundary values of the intervals and all values contained in the interval, as well as subintervals, are directly disclosed.
[0053] The bioengineering methods and techniques of the present invention are generally performed in accordance with conventional approaches well known in the art and as described in various general and more specific references that are cited and discussed throughout the specification unless otherwise indicated. See, for example, Sambrook J. & Russell D. Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2000); Ausubel et al., Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Wiley, John & Sons, Inc. (2002); Harlow and Lane Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1998); and Coligan et al., Short Protocols in Protein Science, Wiley, John & Sons, Inc. (2003).
[0054] References to amino acid residues used in this application are designated by a conventional one-letter or three-letter code (see, e.g., Lehninger, Biochemistry, 2 nd edition, Worth Publishers, New York, 1975, p. 72).
[0055] By "prevention", "prophylaxis", "warning" is meant in a broad sense the prevention of a disease or condition, the elimination or mitigation of one or more symptoms of a disease or condition, the elimination of risk factors for the disease and / or the reduction of the risk of complications of an infection and / or a disease or condition.
[0056] The terms "subject" and "patient" as used herein refer to any mammal, including animals such as livestock, and humans (Homo sapiens), not necessarily suffering from a disease. Preferably, the subject is a primate, most preferably a human.
[0057] "Pharmaceutical compositions" broadly encompass any formulations that include both manufactured compounds (e.g., pharmaceutical substances) and ready-to-use products (medicines). "Pharmaceutical" or "pharmaceutically acceptable" refers to chemical compounds and compositions that are suitable for administration to a mammal, particularly humans, with reduced or avoided adverse, allergic, or other undesirable reactions. Antigen structure Epitopes of target proteins
[0058] CD153 (TNFSF8, CD30LG) is a member of the tumor necrosis factor 8 ligand superfamily. This protein targets senescence-associated T cells in adipose tissue and spontaneous germinal centers. Vaccination against CD153 reduces the number of senescent T cells in adipose tissue, improves glucose tolerance, and enhances the response to endogenous insulin. The authors identified two CTL and two HTL epitopes from CD153 for incorporation into the antigen.
[0059] GPNMB is a glycoprotein protein B specific to non-metastatic melanoma that targets senescent endothelial cells, adipocytes, and leukocytes. GPNMB is associated with aging and is a promising molecular target for senolytic therapy. Immunization against GPNMB improved metabolic parameters, glucose tolerance, and reduced atherosclerotic plaques. The authors identified three CTL and three HTL epitopes from GPNMB for integration into the antigen.
[0060] CD87 (uPAR) is a cell surface receptor for the urokinase plasminogen activator. It targets a broad range of senescent cells. For example, uPAR-positive senescent cells can be safely targeted with senolytic CAR-T cells, and this treatment improves physical performance during physiological aging and reduces metabolic dysfunction in aged mice and in mice on a high-fat diet. The authors identified CTL and HTL epitopes from CD87 for incorporation into antigens.
[0061] CD9 (or Tetraspanin-29) is upregulated in senescent endothelial cells, neointimal hyperplasia, and atherosclerotic plaques. CD9 represents a novel target for the prevention and treatment of vascular aging and atherosclerosis, making it useful as a target in senolytic vaccines. The authors identified two CTL and two HTL epitopes from CD9 for incorporation into antigens.
[0062] KLRG1 (CD94) is a lectin receptor for G1 natural killer cells. KLRG1 is expressed on NK cells and antigen-prone T cells and is thought to be a marker of aging. Elimination of KLRG1-positive cells leads to long-term rejuvenation of the immune system, so the authors included KLRG1 epitopes (1 HTL and 2 CTL) in the vaccine.
[0063] Antigenic epitopes are linked together by flexible and rigid linkers, forming a group of HTL epitopes and a group of CTL epitopes. Auxiliary elements
[0064] In addition to antigenic epitopes, the antigen composition includes the following sequences that help enhance immunogenicity (intramolecular adjuvants).
[0065] HbhA, heparin-binding hemagglutinin, is an adhesin of the bacterium Mycobacterium tuberculosis that exhibits high immunogenicity and the ability to induce a strong humoral and cellular immune response. Incorporation of HbhA into the antigen fusion protein ensures effective antigen recognition by antigen-presenting cells (APCs) due to its natural adhesive properties. The authors believe that HbhA enhances the presentation of the aforementioned antigenic epitopes to the immune system, increasing immunogenicity and the formation of a long-term immune response. In this case, the sequence corresponding to positions 1-159 of WP_003873734 was included.
[0066] The pan-HLA-DR-binding epitope, or PADRE, is a synthetic universal T-cell epitope, AKFVAAWTLKAAA, capable of binding to HLA class II molecules in most individuals, regardless of their haplotype. By incorporating PADRE into the antigen fusion protein, the authors anticipate activating CD4+ T lymphocytes, which is important for both humoral and cellular immunity. Ultimately, PADRE will significantly enhance the immunogenicity of the antigen, ensuring broad population efficacy of the vaccine, making it suitable for use in various regions.
[0067] The Wilms tumor protein epitope (WT33, encoded by the WT1 gene) is an immunodominant epitope of CYTWNQMNL. Its inclusion in the fusion antigen protein ensures a targeted immune response against antigenic targets, increasing the vaccine's specificity. The authors expect the WT33 epitope to promote the activation of cytotoxic T lymphocytes (CD8+) and the elimination of senescent cells.
[0068] The reverse endoplasmic reticulum (ER) transport signal facilitates retrograde protein transport from the Golgi apparatus to the endoplasmic reticulum, increasing its residence time in the antigen processing system. This enhances peptide loading onto MHC class I molecules, improving cross-presentation and activation of CD8+ T cells. The present invention utilizes a KDEL-like sequence, such as KDEL3 (KKDELRDELKDEL). The authors believe that this signal enhances the effectiveness of the antigen in inducing a cellular immune response.
[0069] The combination of HbhA, PADRE, the WT33 epitope and the ER reverse transport signal creates a synergistic effect, providing a potent and balanced immune response against selected senotherapy targets. Linkers
[0070] Protein fragments are separated by rigid and flexible amino acid linkers. Flexible linkers are sequences that provide some degree of mobility or interaction between the fragments being joined, and for this reason, they are primarily composed of small non-polar (e.g., Gly) or polar (e.g., Ser or Thr) amino acids. The inclusion of polar amino acids can maintain linker stability in aqueous solutions by forming hydrogen bonds with water molecules.
[0071] Rigid linkers are defined by specialists as those that maintain distance between fragments to preserve their independent functioning. The rigid structure of such linkers is due to the presence of a helical conformation, such as an α-helix, or the presence of several proline residues. Rigid linkers are generally defined as those characterized by helicity (e.g., α-helicity) of at least approximately 80% (Li, Gang et al. (2016). Construction of a linker library with widely controllable flexibility for fusion protein design. Applied microbiology and biotechnology. 100). In one embodiment, a helicity of less than 80% allows the linker to be used as a flexible linker, however, it is preferred to use linkers with a helicity of less than about 60, 50, 40, 30, 20, 15, 10, 5% and most preferably no helicity (i.e., about 0%).Modeling of the linker structure and its classification as rigid or flexible can be carried out by specialists, for example, using the Discovery Studio 2.5 program (Accelrys, USA).
[0072] Non-exhaustive examples of flexible linkers include: (GGGS) n or (GGGGS) n , where n = 1-9, (GGGGS) n AS, where n = 1-9, AGGGS(GGGGS) n , where n = 1-8, AGGGS(GGGGS) n AS, where n = 1-8, G n , where n = 5-20 (preferably 6 or 8), KESGSVSSEQLAQFRSLD, EGKSSGSGSESKST, GSAGSAAGSGEF, GGSSG, (GS) n , where n = 3-8, GGGGSLVPRGSGGGGS, GGSGGHMGSGG, GG(SGG) n , where n = 1-3, GGSGGGGG, (GGGSE)3GGG, AAGAATAA, GSGGGTGGGSG, (GS)4GGSG, GSGGGTGGGSG, GS(GGS)4, GSGGSGSGGSGGSG and others, as well as their combinations.
[0073] Most preferably, the flexible linkers are selected from (GGGS) n , where n is preferably 1, 2, 3, 4, 5, most preferably 1.
[0074] Non-exhaustive examples of hard linkers include: (EAAAK) n , where n = 1-5; [A(EAAAK) n A] k , where k = 1 or 2, n = 1-5; A(EAAAK)4ALEA(EAAAK)4A; P k (XP) n , where k = 0 or 1, n = 2-34, X is any amino acid, preferably Ala, Lys or Glu, in particular, but not limited to, P k (XP) n can be selected from P(AP) 2-34 , (AP) 2-34 , P(LP) 2-34 , (LP) 2-34 , P(EP) 2-34 , (EP) 2-34 , in particular PAPAP or GPGPG, as well as their combinations.
[0075] Most preferably, the rigid linkers are selected from (EAAAK) n , where n is preferably 1, 2, 3, 4 or 5, most preferably 1, AEAAAKEAAAKA and GPGPG.
[0076] In general, the above-mentioned index n may take any integer value within the range specified for a particular linker, for example, if n = 1-9, then any of 1, 2, 3, 4, 5, 6, 7, 8, 9 is implied.
[0077] It should be noted that flexible units can be present within rigid linkers, provided that the overall rigidity of the structure is maintained, e.g., at least 80% of the linker's helicity is preserved. Specifically, the (GGGGS) unit can be present in combination with four (EAAAK) units, such as (EAAAK)4GGGGS, (EAAAK)3GGGGSEAAAK, (EAAAK)2GGGGS(EAAAK)2, EAAAKGGGGS(EAAAK)3. Similarly, rigid units can be included within flexible linkers, provided that overall structural flexibility is ensured. Using the above links as an example, the following flexible linkers are acceptable, but not limited to the ones indicated: for example, (GGGGS)4EAAAK, (GGGGS)3EAAAKGGGGS, (GGGGS)2EAAAK(GGGGS)2, GGGGSEAAAK(GGGGS)3.
[0078] The total length of the linker, flexible or rigid, between any of the fragments (or subfragments), may preferably be from 5 to 50 amino acid residues, such as from 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25; up to 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6. Most preferably, the length of the linker is 4-12 amino acid residues.
[0079] Effects of spontaneous schizophrenia (Chen X, Zaro JL, Shen WC. Fusion). Adv Drug Deliv 2013 Oct;65(10):1357–69; http: / / dx.doi.org / 10.1037 / 0033-295X.102.2.2013 [ PubMed ] [ Cross Ref ] S, Galimidi RP, Keeffe JR, Bjorkman PJ Feb;22(2):153-67, Linkers in Biomacromolecules Ed. Thanks for reading
[0080] The HTL epitopes and CTL epitopes of CD87, GPNMB, CD9, CD153, and KLRG1 are grouped into corresponding groups, where the HTL epitope group is a sequence consisting of SEQ ID NOs: 4-12, separated from each other by rigid linkers, and the CTL epitope group is a sequence consisting of SEQ ID NOs: 13-22, separated from each other by flexible linkers. When linked to each other, both groups are linked via a flexible and / or rigid linker. In a preferred embodiment, the HTL epitope group, the CTL epitope group, and the WT33 epitope are separated from each other by flexible linkers. The arrangement of epitopes in the group of HTL epitopes and in the group of CTL epitopes is not fundamentally limited, i.e. SEQ ID NO: 4, 5, 6, 7, 8, 9, 10, 11, 12 are arranged in any sequence relative to each other, and SEQ ID NO: 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 are arranged in any sequence relative to each other.In a non-limiting embodiment, in a group of HTL epitopes and / or in a group of CTL epitopes, the epitopes are grouped according to the protein from which they are obtained; preferably, the epitopes are arranged in ascending sequence number (SEQ ID NO) from the N- to the C-terminus.
[0081] The HbhA fragment is located at the N-terminus, meaning that the remaining essential elements of the protein are located towards the C-terminus (to the right); in particular, the HbhA fragment is located at or near the N-terminus of the antigen, separated from the remaining elements by a rigid linker(s), preferably a linker that forms an alpha helix.
[0082] PADRE is located inside the molecule, i.e. between structural elements, in particular between HbhA and a group of HTL or CTL epitopes, separated from them by rigid linkers.
[0083] The WT33 epitope can be located at any internal position, such as adjacent to (or between) a group of HTL epitopes, a group of CTL epitopes, or a reverse ER transport signal, in any embodiment. Most preferably, the WT33 epitope is located near the reverse ER transport signal to further enhance cross-presentation. Preferably, the WT33 epitope is separated from the other elements by flexible linkers.
[0084] The ER reverse transport signal (e.g., KDEL3) must be located at the C-terminus for its proper recognition and protein transport and separated by a flexible linker from the rest of the elements.
[0085] Thus, the protein architecture may be as follows, without limitation: N-terminus123456C-terminus124356123546124536where 1 is the HbhA fragment, 2 is PADRE, 3 is a group of HTL epitopes, 4 is a group of CTL epitopes, 5 is the WT33 epitope, 6 is the signal for reverse transport to the ER.
[0086] In one of the non-limiting embodiments:
[0087] - the HbhA fragment does not necessarily have an EAAAK linker at its N-terminus, but has an AEAAAKEAAAKA linker at its C-terminus,
[0088] - PADRE is flanked by AEAAAKEAAAKA and GPGPG linkers at the N- and C-terminus, respectively;
[0089] - the group of HTL epitopes is flanked by GPGPG and GGGS linkers at the N- and C-terminus, respectively;
[0090] - a group of CTL epitopes are flanked by GGGS linkers at the N- and C-terminus; and / or
[0091] - the WT33 epitope is flanked by GGGS linkers at the N- and C-terminus.
[0092] In general, the protein of the invention may contain one or more additional amino acid residues at the N-terminus, either functional or non-functional. For example, fusion proteins are typically characterized by the presence of a methionine (M) residue at the N-terminus due to the specifics of protein expression and translation initiation, and methionine may be present at the N-terminus of an antigen. Moreover, those skilled in the art are familiar with the so-called "N-terminus rule," which relates the rate of protein degradation to the presence of certain amino acid residues, and it may even be desirable for a skilled artisan to place an additional residue at the N-terminus to increase the half-life of the protein. For use or expression of the protein in mammals, such residues may be V, M, G, P, I, and most preferably V. These residues may be separated from the essential elements of the protein by a linker, either rigid or flexible.For example, in the antigen of the invention, MV residues may be present at the N-terminus, separated from, in particular, the HbhA fragment by a rigid linker, for example EAAAK. Protein as an object
[0093] Although the concept of the invention is best realized using a gene vaccine platform, the immunogenic hybrid protein described above is also an object of the invention in itself and can find application for immunization for the same indications as the nucleic acid molecule of the invention.
[0094] Direct use of a protein may require further modification. It may be an isolated protein, i.e., a single molecule, or part of another molecule, such as a protein or conjugate.
[0095] The conjugate may include molecules, for example, for increasing solubility, for preventing or reducing proteolysis, for detectability, etc., and they may be attached to the C- or N-terminus of the protein of the invention or to an amino acid residue within the sequence of the protein of the invention. Conjugated molecules include, but are not limited to, biotin, polyethylene glycol, nucleic acids, polysaccharides, and proteins of other organisms. Conjugation may be direct or indirect (e.g., via a linker). The protein may include additional functional sequences at the N- or C-terminus or within the protein sequence, such as peptide tags designed to alter solubility (e.g., increase it), purify or immobilize the protein (in particular, affinity tags), signal peptides, for example, for transporting the peptide to a specific position in the producer cell or outside it, for visualization / tracking of the protein.Peptide tags are typically short sequences, but in some cases they can represent entire proteins, such as enzymes. After purification, peptide tags can be removed, if necessary, using known methods, or self-cleaving tags can be used. Additional information regarding peptide tags and the nuances of their use in hybrid proteins is well known to specialists (Wood DW (2014) New trends and affinity tag designs for recombinant protein purification. Curr Opin Struct Biol 26: 54–61; Pina AS, et al. (2014) Affinity tags in protein purification and peptide enrichment: An overview. Methods in molecular biology (Clifton, NJ) 1129: 147–168; Xi Han, Wenbo Ning, Xiaoqiang Ma, Xiaonan Wang, Kang Zhou. Improving protein solubility and activity by introducing small peptide tags designed with machine learning models. Metabolic Engineering Communications, Volume 11, 2020).
[0096] The above-considered functionalization of the protein according to the invention will be determined primarily by the specific purposes for which the protein is planned to be used, the methods of production and purification, etc.
[0097] Preferably, the immunogenic protein corresponds in sequence to the protein encoded by the nucleic acid molecule of the invention. In one preferred embodiment, the protein has the sequence SEQ ID NO: 1. For diagnostic and research applications, the skilled artisan may, if necessary, incorporate one or more of the modifications discussed above or other known modifications into the protein.
[0098] The means and methods for obtaining recombinant proteins are known to those skilled in the art (Rosano GL, Ceccarelli EA. Recombinant protein expression in microbial systems. Front Microbiol. 2014 Jul 8;5:341; Wingfield PT. Overview of the purification of recombinant proteins. Curr Protoc Protein Sci. 2015 Apr 1;80:6.1.1–6.1.35; Saraswat, Mayank, Musante, Luca, Ravida, Alessandra, Shortt, Brian, Byrne, Barry, Holthofer, Harry, Preparative Purification of Recombinant Proteins: Current Status and Future Trends, BioMed Research International, 2013, 312709).
[0099] The immunogenic protein may also be an ingredient of the pharmaceutical composition of the invention and an active principle for use in one or more of the indications disclosed herein. Nucleic acid molecule design options
[0100] While the beneficial effects of the invention are primarily due to the design of the antigen encoded by the nucleic acid molecule of the invention, the specific embodiment of the nucleic acid molecule is not essential, provided that the nucleic acid molecule can be delivered to the body's cells and ensure the expression of the antigen. Thus, the invention encompasses any variants of vectors and similar platforms suitable for use as gene vaccines: plasmid vectors, viral vectors, RNA, in particular mRNA or its self-amplifying analogs, but is not limited to the above.In addition, nucleic acid molecules of other purposes, although not directly suitable for use as vaccines, but useful in some other respect, such as technological or production, in particular for the transfer of genetic information about an antigen into a specific cell, for cloning, for insertion into a larger molecule, such as in the form of a cassette, are also covered by the term "nucleic acid molecule".
[0101] In the case of nucleic acid molecules intended for expression, the antigen-encoding sequence must be "operably linked" to regulatory or control sequences that direct protein transcription and translation, i.e., transcription and / or translation of the coding sequence is influenced or controlled by regulatory or control sequences. A "control sequence" may be any element, such as, but not limited to, promoters, enhancers, IRES (internal ribosome entry site), introns, etc. Expression of the antigen according to the invention may be under the control of a constitutive promoter or an inducible promoter, which initiates transcription only when exposed to, for example, antibiotics, hormones, etc. The promoter may also be specific to a particular cell type, tissue, or organ.Many promoters and enhancers suitable for the invention are known in the art: see, for example, the Eukaryotic Promoter Database (EPDB).
[0102] The plasmid may be, for example, a cloning plasmid or an expression plasmid. The viral vector may, in particular, be a vector based on an adenovirus, lentivirus, retrovirus, adeno-associated virus, smallpox virus, rubella virus, Sendai virus, rabies virus, alphavirus, herpes virus, etc. In particular, the vector may be selected from a CMV vector, for example, an RhCMV or HCMV vector. The RNA may be messenger RNA (mRNA), self-amplifying RNA (saRNA), or transamplifying RNA (taRNA, for example, an antigen-encoding transcript).
[0103] Details on the design and methods for producing the above and other types of nucleic acid molecules are known to those skilled in the art from the literature, for example, Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev. 2011 Jan;239(1):62-84; Kutzler, M., Weiner, D. DNA vaccines: ready for prime time?. Nat Rev Genet 9, 776–788 (2008); Lundstrom K. Viral Vectors in Gene Therapy. Diseases. 2018 May 21;6(2):42. Bulcha, JT, Wang, Y., Ma, H. et al. Viral vector platforms within the gene therapy landscape. Sig Transduct Target Ther 6, 53 (2021); Pardi, N., Hogan, M., Porter, F. et al. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov 17, 261–279 (2018); Sahin, U., Karikó, K. & Türeci, Ö. mRNA-based therapeutics — developing a new class of drugs. Nat Rev Drug Discov 13, 759–780 (2014); Bloom, K., van den Berg, F. & Arbuthnot, P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther 28, 117–129 (2021).
[0104] The invention also relates to a method for producing a nucleic acid molecule according to the invention, which generally comprises culturing a host cell containing said molecule under conditions conducive to increasing cell biomass, isolating the nucleic acid molecule from the biomass and purifying it; and to said host cell. The host cell carries genetic information about the antigen and can optionally produce it. The purpose of the cell is not fundamentally limited: it is intended both for production purposes - for obtaining the nucleic acid molecule according to the invention, and for the purpose of maintaining genetic information in a culture collection. Cells herein are understood to mean cell strains or lines, or a combination thereof. The type of cell is not particularly limited, and it can be a prokaryotic or eukaryotic cell, for example yeast such as S. cerevisiae, P. pastoris, bacteria such as E.coli (e.g. DH5α, TOP10, BL21(DE3), JM109, HB101, Rosetta), insect cells (Sf9, Sf21), animal cells such as mammalian cells, in particular human (e.g. HEK293, PER.C6, HT-1080) or hamster (CHO, BHK-21) and other species (Vero, CEF).
[0105] mRNA vaccines can also be produced in cell-free systems using in vitro transcription, for example with T7 / SP6 RNA polymerase.
[0106] Briefly, plasmid vector-based DNA vaccines typically include: a promoter (CMV (e.g., hCMV), SV40, EF1α, etc.) that drives expression of the target gene in the cells of the host to which the vaccine is administered; a target gene (antigen); a polyadenylation signal (e.g., from SV40, BGH, etc.) that stabilizes the mRNA; an origin of replication or ori for amplification in the host (producer) cell, such as E. coli; and a selectable marker (e.g., a gene for resistance to a particular antibiotic).
[0107] The method for producing DNA vaccines based on plasmid vectors typically includes:
[0108] - cloning of the target gene into a plasmid vector using restriction enzymes and DNA ligases;
[0109] - transformation into a competent host cell, such as E. coli, such as strain DH5α;
[0110] - cell cultivation for biomass production, cell lysis and plasmid isolation;
[0111] - purification (e.g. ethanol precipitation, chromatography);
[0112] - creation of a drug (for example, a solution of a certain concentration in water or an aqueous solution with auxiliary substances, such as a buffer, in particular phosphate buffered saline, a preservative, etc.).
[0113] Recombinant viral vectors can be obtained on the basis of adenoviruses, lentiviruses, adeno-associated viruses (AAV), herpes simplex virus (HSV), retroviruses, alphaviruses, flaviviruses, rhabdoviruses, measles viruses, Newcastle disease viruses (NDV), Coxsackie viruses, poxviruses, etc.
[0114] Typical elements of viral vectors include: a target gene (inserted in place of viral genes); a promoter (universal or tissue-specific); ITR sequences (for packaging the viral genome); packaging genes (e.g., in a separate plasmid for production).
[0115] The method for producing viral vectors typically includes:
[0116] - construction of a recombinant genome (replacement of viral genes with a target gene);
[0117] - transfection of packaging cells (e.g. HEK293 for adenoviruses);
[0118] - collection and purification of viral particles (ultracentrifugation, chromatography);
[0119] - titration (qPCR, infectious units).
[0120] mRNA vaccines typically include: a 5' cap; 5' and 3' UTRs (untranslated regions); a coding region; and a poly(A) tail (e.g., 100-150 nucleotides).
[0121] To deliver mRNA vaccines, they are packaged, for example, in lipid nanoparticles (LNPs) or carriers such as lipids and polymers are used; or electroporation is used.
[0122] A method for producing mRNA may typically include:
[0123] - in vitro transcription (T7 / SP6 RNA polymerase);
[0124] - purification (DNase, LiCl precipitation);
[0125] - formation of LNP (microfluidic technology, ethanol injection) or other carrier;
[0126] - sterile filtration.
[0127] saRNA typically includes 5'- and 3'-CSE (cis-regulatory sequences) instead of 5'- and 3'-UTR, nsP1-4 genes, a subgenomic promoter, a coding sequence, and poly(A). taRNA refers to a combination of two transcripts, one containing the nsP1-4 genes and the other the coding sequence, with a translation-amplification scheme similar to saRNA.
[0128] When creating a nucleic acid molecule according to the invention, the person skilled in the art should take into account that for use in a particular organism, codon optimization may be necessary, i.e., reworking its sequence to increase the efficiency of antigen expression in heterologous systems (e.g., in bacterial, yeast, or mammalian cells). Since different organisms prefer certain codons with different frequencies, replacing rare codons with more common ones in the host organism can significantly increase the level of translation and the correctness of protein folding. Optimization methods are known to those skilled in the art (e.g., Gustafsson C, Govindarajan S, Minshull J. Codon bias and heterologous protein expression. Trends Biotechnol. 2004 Jul;22(7):346-53) and include not only algorithmic codon selection but also the elimination of interfering secondary structures, balancing the GC content, and avoiding repetitive sequences.Specialists can use various services to perform optimization of the sequence according to the invention, such as GeneOptimizer, OPTIMIZER, CodonW IDT Codon Optimization Tool, Twist Bioscience Codon Optimization, SnapGene, DeepCodon.
[0129] The nucleic acid molecule of the invention may be codon-optimized (including one or more of the above or other optimization methods) or codon-non-optimized. Pharmaceutical compositions
[0130] In this document, pharmaceutical compositions are broadly understood to encompass any formulations suitable for use in human health, veterinary medicine, and scientific research. Accordingly, the invention encompasses medicinal products, drugs, pharmaceutical substances, intermediates, etc. Pharmaceutical compositions are intended for use in animals, including mammals, in particular humans. Accordingly, pharmaceutical compositions comprise an active substance according to the invention (primarily a nucleic acid molecule according to the invention) in an effective amount and one or more pharmaceutically (therapeutically or veterinarily) acceptable excipients. Optionally, the composition may contain additional active substances and / or adjuvants.
[0131] The composition may be administered parenterally or enterally. Typical routes of administration of the composition include, but are not limited to, injection (such as subcutaneous, intramuscular, intradermal, intraperitoneal, and intravenous), oral, sublingual, buccal, rectal, transdermal, intranasal, vaginal, inhalation, and others.
[0132] "Pharmaceutically acceptable excipient" is conventionally used for such compositions (see, particularly, Remington's Pharmaceutical Sciences by E.W. Martin, Mack Publishing Co., Easton, PA, 19th Edition, 1995). Excipients include a solid, soft, or liquid filler or carrier, diluent, stabilizer, preservative, antioxidant, solvent, surfactant, emulsifier, buffer, colorant, acidity regulator, or other auxiliary substance of any type. The choice of excipient will depend on the particular route of administration employed and the type of active ingredient selected. For example, parenteral formulations typically contain injection liquids, which include pharmaceutically and physiologically acceptable liquids such as water, physiological saline and other salt solutions, buffers, aqueous dextrose solution, glycerol, and the like, as a carrier.In the case of solid compositions (such as powders, tablets, capsules, lyophilisates), excipients may include, for example, mannitol, lactose, starch, magnesium stearate, etc.
[0133] The pharmaceutical compositions of the invention may be in the form of a lyophilisate suitable for the preparation of a solution by adding sterile water or another suitable solvent immediately before administration of the composition.
[0134] The dosage form of the composition according to the invention may be dosed (metered) or non-metered. The dosage form may be a standard single dose, such as an ampoule containing a single-dose solution or lyophilisate.
[0135] The pharmaceutical composition or its individual components may be presented in the form of a kit comprising a nucleic acid molecule (e.g., in the form of a composition) and, if necessary, one or more of the following components: additional substances required to create a dosage form ready for administration, such as water or another solvent, such as a buffer solution; instructions for use, means for administration, such as a syringe, dropper, etc.; a disinfectant, etc. The kit is packaged in suitable packaging, and the components are contained in appropriate containers, such as vials, ampoules, blisters, ready-to-use devices (syringes, etc.).
[0136] A non-limiting example of a pharmaceutical composition according to the invention is a solution comprising 1 mg / ml of plasmid (SEQ ID NO:29), 0.9% NaCl (isotonic), 0.9% benzyl alcohol (preservative), and water for injection. The composition is aseptically packaged in 1 ml single-use glass ampoules.
[0137] The purpose of the composition may be selected from any one or more of the purposes disclosed herein. Methods of vaccination and treatment
[0138] The present invention also relates to methods involving administering to a subject a nucleic acid molecule described herein.
[0139] Since senescent cells appear early, there is no age limit for the subject. However, the effect of senescent cells on the body clearly increases with age, making the invention most suitable for use in middle-aged and elderly subjects. Specifically, subjects may be 20 years of age, preferably 30, 40, 50, 60, or older.
[0140] First, a method of senotherapy (also known as "anti-aging therapy") and a method of vaccination are disclosed, broadly aimed at combating aging, in particular the senescent phenotype, by targeting the immune system to destroy senescent cells in the body. Specifically, the methods are intended to prevent or combat the manifestation of one or more symptoms of aging, to reduce their severity, to prevent or combat dysfunction of the body caused by aging, to slow aging, to delay the onset or development of aging symptoms, and / or to combat the SASP phenotype.
[0141] Symptoms of aging may include, but are not limited to, the appearance of wrinkles and folds, dry and thinning skin, age spots, graying and hair loss, deterioration of nails, loss of muscle mass, decreased body tone, changes in posture due to, for example, osteoporosis or spinal degeneration, loss of tissue volume due to atrophy of subcutaneous fat;cognitive decline, such as memory impairment, slowed thinking, impaired vision and hearing, decreased muscle strength and endurance, decreased metabolism, weight gain or loss, changes in glucose tolerance, impaired cardiovascular function, including atherosclerosis, decreased vascular elasticity, hypertension, decreased lung function, gastrointestinal dysfunction, weakened immune function, including increased susceptibility to infections, delayed wound healing, hormonal changes, decreased bone density, increased risk of fractures, sleep disturbances, decreased libido and reproductive function. As can be seen, the scope of the invention includes not only purely therapeutic methods, but also, primarily, cosmetic ones.
[0142] In addition, the methods of the invention include methods for prolonging lifespan, which may include, in particular, prolonging lifespan until the time of death and / or increasing the quality of life over time, including the period of healthy and / or functional life, or the level of satisfaction with the quality of life.
[0143] In another embodiment, a method is provided for inducing an immune response in a subject against one or more or all of the targets from which the antigen of the invention is derived (i.e., CD87, GPNMB, CD9, CD153 and KLRG1).
[0144] Another embodiment provides a method for treating or preventing a disease or condition associated with one or more of the above targets. In this case, "associated" is understood in the broadest sense and refers not only to the involvement of the target in the development of the pathology but also, in general, to any benefit from therapy directed at the target.The prior art contains numerous studies indicating the potential of immunization against CD87, GPNMB, CD9, CD153 and KLRG1 in the following associated diseases and conditions: tumor (cancer), metastatic tumors (in particular colorectal cancer, glioblastoma, lung cancer, melanoma, breast cancer, in particular triple negative or metastatic cancer, ovarian cancer), lymphoproliferative diseases (Hodgkin's lymphoma, anaplastic large cell lymphoma); inflammatory diseases (atherosclerosis, rheumatoid arthritis); fibrosis (liver, lung, kidney); infections, including bacterial and viral; neurodegenerative diseases (Parkinson's and Alzheimer's diseases); osteoporosis and osteoarthritis; autoimmune diseases (in particular multiple sclerosis, rheumatoid arthritis, lupus); thrombosis; atopic diseases (eczema, allergic reactions); pathologies associated with the aging of the immune system.
[0145] The invention includes the use of the disclosed nucleic acid molecule as a medicinal product for senotherapy (or in accordance with any of the above-mentioned indications), as well as a substance for the manufacture of such a medicinal product.
[0146] All of the above and other methods described herein include the step of administering to a subject in need thereof a nucleic acid molecule of the invention (in other embodiments, an immunogenic protein of the invention may be administered) in an effective amount. The methods may further include administering other active substances or supplements to the subject, prescribing diets, or applying any therapeutic or cosmetic treatments to the subject. In particular, the methods of the invention may be combined with the administration of other senolytics or senomorphics, such as a combination of dasatinib and quercetin and / or fisetin.
[0147] Effective doses of the nucleic acid molecule of the invention are determined by those skilled in the art in accordance with recommendations of regulatory agencies (e.g., FDA Guidelines, EMA Guidelines, Recommendations of the Ministry of Health of the Russian Federation) taking into account the species and weight of the organism, as well as the platform (DNA vaccines, mRNA vaccines, and viral vector vaccines may require different doses). Dose conversion between animals and humans can be performed according to known methods (e.g., Nair AB, Jacob S. A simple practice guide for dose conversion between animals and humans. J Basic Clin Pharm. 2016 Mar;7(2):27-31).
[0148] In non-limiting embodiments, vaccines may have the following dose (single administration) for humans:
[0149] DNA vaccine, such as a plasmid: 0.5-10 mg, such as 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3, 3.5 or 4.0 mg, and up to 10, 9.5, 9.0, 8.5, 8.0, 7.5, 7.0, 6.5, 6.0, 5.5, 5.0 or 4.5 mg, such as 1-4 mg, preferably 1 mg.
[0150] mRNA vaccines: 10-100 mcg, for example 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 or 70 mcg, and up to 100, 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30 mcg.
[0151] Viral vector vaccines, such as adenovirus: 1×10 10 -1×10 11 viral particles (VP), for example 2×10 10 , 3×10 10 , 4×10 10 , 5×10 10 , 6×10 10 , 7×10 10 , 8×10 10 , 9×10 10 , including any ranges formed by these values.
[0152] The number of administrations is essentially unlimited. Typically, to enhance or prolong the immune response, it is desirable or necessary to administer more than one dose of the vaccine, for example, 2, 3, 4, 5, or more, preferably three times. The initial dose is typically referred to as the "prime" dose, and any subsequent doses are referred to as "booster" doses. A booster dose can be administered, for example, approximately 1, 2, 3, or 4 weeks or more after the prime dose, preferably every 2 weeks. In some embodiments, the vaccine is administered regularly throughout life, for example, annually or every few years.
[0153] Non-limiting examples of the recommended starting dose of the plasmid vaccine according to SEQ ID NO:29 and dosing regimen:
[0154] - for animals: 200 mcg, three times, once every 2 weeks;
[0155] - for humans: 1 mg, three times, once every 2 weeks.
[0156] Table 1. Sequences SEQ ID NO: Explanation 1 Antigen encoded by the plasmid according to the Examples 2 HbhA fragment (heparin-binding hemagglutinin of Mycobacterium avium) 3 pan-HLA DR-binding epitope (PADRE) 4 HTL-epitope CD875 HTL-epitope GPNMB6 HTL-epitope GPNMB7 HTL-epitope GPNMB8 HTL-epitope CD99 HTL-epitope CD910 HTL-epitope CD15311 HTL-epitope CD15312 HTL-epitope KLRG113 CTL-epitope GPNMB14 CTL-epitope GPNMB15 CTL-epitope GPNMB16 CTL-epitope KLRG117 CTL-epitope KLRG118 CTL-epitope CD15319CTL epitope CD15320CTL epitope CD8721CTL epitope CD922CTL epitope CD923Wilms tumor protein (WT33) epitope, activator of T-cell immunity24KDEL3 signal25rigid linker26rigid linker27rigid linker28flexible linker29plasmid according to Examples
[0157] : Plasmid map according to SEQ ID NO:29. Legend: ori – plasmid replication origin; CMV enhancer – human cytomegalovirus enhancer; CMV promoter – human cytomegalovirus promoter; T3 promoter – promoter for bacteriophage T3 RNA polymerase; antigen – sequence encoding protein according to SEQ ID NO:1; f1 ori – bacteriophage f1 replication origin; bGH poly(A) signal – bovine growth hormone polyadenylation signal; T7 promoter – promoter for bacteriophage T7 RNA polymerase; SV40 ori – SV40 virus replication origin; SV40 promoter – promoter and early enhancer of SV40 virus; AmpR promoter – ampicillin resistance gene promoter, NeoR / KanR – neomycin / kanamycin resistance gene; HSV TK poly(A) signal – herpes simplex virus thymidine kinase polyadenylation signal; BamHI, XhoI – restriction sites.
[0158] : Survival curves for three groups from the experiment.
[0159] Example 1: Protocol for plasmid production, isolation and purification
[0160] Plasmid DNA was constructed using the pCMV vector, into which the antigen-encoding sequence (SEQ ID NO: 1) was inserted at sites recognized by the BamHI and XhoI restriction enzymes. A map of the resulting plasmid is shown in [image missing], and its characteristics are summarized in Table 3 below:
[0161] Table 2. Characteristics of the resulting plasmid Parameter Value Vector pCMV-3 Tag-3a Antibiotic resistance Neomycin / Kanamycin Cloning sites BamHI, XhoI Insert length, bp 2214 Plasmid length, bp 6398 Complete nucleotide sequence SEQ ID NO: 29
[0162] Preparation of competent E. coli cells and their transformation with the resulting plasmid DNA by electroporation were performed according to standard methods. After subculture in a medium containing the appropriate antibiotic, colonies of successfully transformed cells were obtained.
[0163] Biomass cultivation
[0164] The transformed cells were used for biomass production according to the parameters below.
[0165] Equipment:
[0166] Fermenter with a working volume of 40 l;
[0167] Spectrophotometer with wavelength A-540;
[0168] Flow centrifuge with 2.0 L rotor.
[0169] Solutions:
[0170] Nutrient medium (for 25 l): Yeast extract 125 g (0.5%) Meat peptone 250 g (1%) Glycerin 750 ml (3%) Ampicillin 0.8 g (0.0032%) before sowing + 0.8 g (0.0032%) after 5 hours of cultivation NaCl 250 g (1%) K2HPO 4 25 g (0.1%) MgSO 45 g (0.02%) Glucose 150 g (0.6%) pH stabilizers: NH4OH 25% H3PO 4 85% Fermentation parameters: Temperature 37 °C pH 7.0 O2 index 25 pO2 100 Measurements are taken at the time of sowing, after 15 hours and then every hour
[0171] When the optical density (A-540) reaches above 5.0, cultivation is stopped. The cells are pelleted by centrifugation in a continuous-flow centrifuge.
[0172] Isolation of plasmid DNA
[0173] Working solutions:
[0174] Solution 1: 10 mM Tris-HCl, 1% glucose / sucrose, pH 8.0;
[0175] Solution 2: 0.2N NaOH, 1% SDS;
[0176] Solution 3: 10 M ammonium acetate;
[0177] Isopropanol.
[0178] Selection procedure:
[0179] The cells were thoroughly resuspended in Solution 1 (at a rate of 10 ml of Solution 1 per 1 g of wet biomass) until complete homogeneity was achieved and there were no cell agglomerates in the resulting suspension.
[0180] Solution 2 was added (at a rate of 10 ml of Solution 2 per 1 g of wet biomass) and gently mixed for 5-7 minutes until a viscous, homogeneous solution was obtained. Incubation time at this stage should not exceed 10 minutes.
[0181] Cooled Solution 3 was added sharply (at the rate of 10 ml of Solution 3 per 1 g of wet biomass) and stirred until the viscosity of the solution completely disappeared and white flakes appeared in the solution.
[0182] The solution was filtered through a capsule filter (0.45 µm) or centrifuged at 12,000×g for 30 min at 15°C. The supernatant was transferred to a clean container, taking care not to capture the sediment. For large volumes of extraction, the supernatant was additionally filtered.
[0183] Optionally, the solution can be concentrated using tangential cells (100 kDa).
[0184] 0.6 volumes of isopropanol were added to the resulting supernatant, mixed well, and the mixture was incubated for 20 minutes at -20°C.
[0185] Centrifuged at 12000×g for 30 min at +15°C. The supernatant was removed.
[0186] The test tubes (centrifuge cups) were dried until the smell of isopropanol disappeared.
[0187] The plasmid pellet was dissolved in nuclease-free water.
[0188] The presence of plasmid DNA was monitored using horizontal electrophoresis in agarose gel.
[0189] The plasmid solution was treated with RNase A (final RNase concentration - 0.1 mg / ml) and the solution was incubated for 3-4 hours at 37°C, then overnight at +4°C.
[0190] The presence of RNA in the plasmid DNA solution was monitored using horizontal electrophoresis in agarose gel.
[0191] Purification of plasmid DNA
[0192] Equipment:
[0193] Akta Purifier 100 GE Healthcare Chromatograph
[0194] Chromatographic column AXIOMA PSK-50-240 Q Sepharose FF
[0195] Chromatographic column AXIOMA-ND-50 / 280 Butyl Sepharose FF
[0196] Peristaltic pump LongerPump WT 600-2J
[0197] Capsule filter 0.22 microns
[0198] Eppendorf 5910R Centrifuge with Angle Rotor FA-6x250
[0199] Spectrophotometer Ekros PE-5400 UV
[0200] Purification of plasmid DNA by anion exchange chromatography
[0201] Solutions:
[0202] Buffer 1M Tris-HCl pH 8.0
[0203] Buffer 0.5M Tris-HCl pH 8.0
[0204] Buffer 50mM Tris-HCl 0.5M NaCl pH 8.0
[0205] Buffer 50mM Tris-HCl 1.5M NaCl pH 8.0
[0206] 1M NaOH
[0207] 30% Isopropanol
[0208] 20% Ethanol
[0209] 1M Tris-HCl pH 8.0 was added to the plasmid DNA solution obtained from the lysis stage to a final concentration of 50 mM and NaCl to a final concentration of 0.5 M. The resulting solution was filtered through a capsule filter with a pore size of 0.22 μm.
[0210] An AXIOMA PSC-50-240 chromatography column with Q Sepharose FF sorbent (GE Healthcare) was washed with 2 volumes of 0.5 M Tris-HCl buffer pH 8.0, 1 volume of 50 mM Tris-HCl 1.5 M NaCl buffer pH 8.0 and equilibrated with 50 mM Tris-HCl 0.5 M NaCl buffer pH 8.0 (Buffer A). The sample was applied at 25 ml / min, and the breakthrough was collected for subsequent analysis on a 1% agarose gel. After sample application, the column was washed with 3 volumes of buffer A. Then a gradient of buffer B (50 mM Tris-HCl 1.5 M NaCl pH 8.0) from 0 to 100% B was applied over 120 min at 25 ml / min. At a conductivity of 57–58 mS / cm, the peak containing plasmid DNA began to be collected.
[0211] After completion of chromatographic purification, the column was washed with 2 volumes of 1M NaOH solution and left for 6-12 hours, then the column was washed with 3 volumes of water, 2 volumes of 30% isopropanol, 2 volumes of 20% ethanol (storage buffer).
[0212] The DNA concentration in the resulting sample was measured using absorbance at 260 nm, absorbance at 230 nm, and absorbance at 280 nm. The amount of DNA obtained was calculated.
[0213] Purification of plasmid DNA by hydrophobic interaction chromatography
[0214] Solutions:
[0215] Buffer 50 mM Tris-HCl 3M Ammonium Sulfate
[0216] 50 mM Tris-HCl 1 M Ammonium Sulfate
[0217] 1M NaOH
[0218] 30% Isopropanol
[0219] 20% Ethanol
[0220] Dry ammonium sulfate was added to the plasmid DNA solution obtained during anion exchange chromatography with stirring to a final concentration of 3 M. The resulting solution was filtered through a 0.22 µm filter.
[0221] An AXIOMA-ND-50 / 280 chromatographic column with Butyl Sepharose FF sorbent (GE Healthcare) was washed with two volumes of water and equilibrated with three volumes of 50 mM Tris-HCl, 3 M ammonium sulfate (Buffer A). The sample was applied at a flow rate of 25 ml / min. The column was washed with two volumes of buffer A and a gradient of 70% 50 mM Tris-HCl, 1 M ammonium sulfate (Buffer B) was added. The fraction corresponding to plasmid DNA was collected.
[0222] After completion of chromatographic purification, the column was washed with 2 volumes of 1M NaOH solution and left for 6-12 hours in this solution, then the column was washed with 3 volumes of water, 2 volumes of 30% isopropanol, 2 volumes of 20% ethanol (storage buffer).
[0223] The DNA concentration in the resulting sample was measured using absorbance at 260 nm, absorbance at 230 nm, and absorbance at 280 nm. The amount of DNA obtained was calculated.
[0224] Buffer change by anion exchange chromatography
[0225] Solutions
[0226] Buffer 50 mM Tris-HCl pH 8.0
[0227] Buffer 50 mM Tris-HCl 1M NaCl pH 8.0
[0228] 1M NaOH
[0229] 30% Isopropanol
[0230] 20% Ethanol
[0231] The AXIOMA PSK-50-240 chromatographic column with Q Sepharose FF sorbent (GE Healthcare) was washed with 2 volumes of 0.5 M Tris-HCl buffer pH 8.0, 1 volume of 50 mM Tris-HCl 1.5 M NaCl buffer pH 8.0 and equilibrated with 50 mM Tris-HCl buffer pH 8.0 (Buffer A).
[0232] The DNA solution was applied to the column at 30 ml / min and washed with 5 volumes of buffer A. A gradient of 100% buffer 50 mM Tris-HCl, 1 M NaCl, pH 8.0 (Buffer B) was added. The fraction containing plasmid DNA was collected.
[0233] After completion of chromatographic purification, the column was washed with 2 volumes of 1M NaOH solution and left for 6-12 hours, then the column was washed with 3 volumes of water, 2 volumes of 30% isopropanol, 2 volumes of 20% ethanol (storage buffer).
[0234] Reprecipitation of plasmid DNA
[0235] An equal volume of isopropanol was added to the resulting plasmid DNA solution and left at room temperature for 2 hours. The resulting preparation was centrifuged at 14,000 rcf (relative centrifuge acceleration) for 15 minutes, the supernatant was removed, and the plasmid DNA precipitate was washed with cold 70% ethanol, centrifuged at 14,000 rcf for 15 minutes, the supernatant was removed, and the precipitate was dissolved in an appropriate volume of water for injection.
[0236] The optical density of the resulting solution was measured at 260 nm, 230 nm, and 280 nm, and the concentration and amount of plasmid DNA obtained were calculated. Water for injection was used to adjust the concentration to a final value of 1 mg / ml.
[0237] Example 2: Survival Study
[0238] Three groups of mice, each containing 30 individuals, were studied. At 8 months of age, the animals were vaccinated three times with the study vaccine (SEQ ID NO:29) for the experimental group ("DNA vaccine"), saline for the control group ("control"), and an empty vector preparation for the "empty vector" control group (a plasmid corresponding to the study one, but into which the antigen was not inserted) every 2 weeks at a dose of 100 μg in each hind leg. The survival age of the experimental animals was recorded in months. Survival curves were compared using the log-rank test.
[0239] The χ² value was 17.14, corresponding to a p value of 0.00019, indicating that the differences between the control and experimental groups are significant. The survival curve is presented in Fig.
[0240] Thus, the introduction of the vaccine significantly increases the life expectancy of animals, on average from 2.1 to 3.2 years.
[0241] The examples presented above are not intended to limit the scope of the claims, which are defined primarily by the claims and the general concept underlying the invention. A skilled person may, using the means and methods disclosed herein and known in the art, create various alternative embodiments of any of the inventive subjects, which are also within the scope of the claims.
Claims
A recombinant nucleic acid molecule encoding an immunogenic protein, wherein the protein comprises a HbhA fragment, PADRE (a pan-HLA DR-binding epitope), a group of HTL epitopes CD87, GPNMB, CD9, CD153 and KLRG1, a group of CTL epitopes CD87, GPNMB, CD9, CD153 and KLRG1, a WT33 epitope and a reverse endoplasmic reticulum transport signal, separated from each other by linkers, wherein: - the HbhA fragment is SEQ ID NO: 2; - PADRE is SEQ ID NO: 3; - the group of HTL epitopes CD87, GPNMB, CD9, CD153 and KLRG1 is a sequence consisting of SEQ ID NOs: 4-12, separated from each other by rigid linkers; - the group of CTL epitopes CD87, GPNMB, CD9, CD153 and KLRG1 is a sequence consisting of SEQ ID NO:13-22 separated from each other by flexible linkers; - the WT33 epitope is SEQ ID NO:23; - the reverse endoplasmic reticulum transport signal is SEQ ID NO:24;The HbhA fragment is located at the N-terminus and is separated from PADRE by a rigid linker; PADRE is separated from the group of HTL or CTL epitopes by a rigid linker; the signal for reverse transport into the endoplasmic reticulum is located at the C-terminus and is separated by a flexible linker. The nucleic acid molecule of claim 1, wherein the rigid linkers in each instance are independently selected from (EAAAK) n , where n = 1-5; [A(EAAAK) n A] k , where k = 1 or 2, n = 1-5; A(EAAAK)4ALEA(EAAAK)4A; P k (XP) n , where k = 0 or 1, n = 2-34, X is any amino acid, preferably Ala, Lys or Glu, preferably rigid linkers are selected from EAAAK, AEAAAKEAAAKA or GPGPG; and flexible linkers are selected from (GGGS) n or (GGGGS) n , where n = 1-9, (GGGGS) n AS, where n = 1-9, AGGGS(GGGGS) n , where n = 1-8, AGGGS(GGGGS) n AS, where n = 1-8, G n , where n = 5-20, KESGSVSSEQLAQFRSLD, EGKSSGSGSESKST, GSAGSAAGSGEF, GGSSG, (GS) n, where n = 3-8, GGGGSLVPRGSGGGGS, GGSGGHMGSGG, GG(SGG) n , where n = 1-3, GGSGGGGG, (GGGSE)3GGG, AAGAATAA, GSGGGTGGGSG, (GS)4GGSG, GSGGGTGGGSG, GS(GGS)4, GSGGSGSGGSGGSG, preferably the flexible linkers are selected from GGGS. A nucleic acid molecule according to claim 1, which is a plasmid vector, in particular a cloning plasmid or an expression plasmid; a viral vector, preferably an adenoviral vector, a lentiviral vector, a retroviral vector, an adeno-associated viral vector; or RNA, in particular mRNA, self-amplifying RNA or transamplifying RNA. A nucleic acid molecule according to claim 1, which is a plasmid with the sequence SEQ ID NO:
29. A pharmaceutical composition containing a nucleic acid molecule according to any one of claims 1, 2 or 4 in an effective amount and one or more excipients. A method of senotherapy comprising administering to a subject in need thereof an effective amount of the pharmaceutical composition according to paragraph 5. A host cell for producing a nucleic acid molecule according to any one of claims 1 to 4, which contains said nucleic acid. A method for producing a nucleic acid molecule according to any one of claims 1-4, comprising culturing the host cell according to claim 7 under conditions that promote an increase in cell biomass, isolating the nucleic acid molecule from the biomass and purifying it. The use of a nucleic acid molecule according to any one of claims 1, 2 or 4 as a medicinal product for senotherapy.
